An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007114/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as
measured by overall response rate (ORR) in adult participants with relapsed and/or refractory
follicular lymphoma (FL).
提供机构：
Vivli
创建时间：
2021-05-06
